Tissue Collection Framework To Improve Outcomes In Solid Tumours
Launched by QUEEN MARY UNIVERSITY OF LONDON · Jun 18, 2018
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Tissue Collection Framework To Improve Outcomes In Solid Tumours," is focused on understanding why some cancers spread and become resistant to treatments. Researchers want to collect tissue samples and blood from patients diagnosed with solid tumors. By analyzing these samples using advanced technologies, they hope to uncover the biological reasons that allow cancer cells to grow and resist therapy. This knowledge could lead to better treatments in the future that not only work more effectively but also help predict which treatments might be best for individual patients.
To participate in this trial, you need to be at least 18 years old and have been diagnosed with a solid tumor while receiving care at Barts Health NHS Trust. This study is currently looking for participants, so if you qualify, you can expect to provide tissue samples during your routine medical care. These samples will be tested and stored for future research. It’s important to note that while participating could help advance cancer treatment, individuals with certain medical conditions or mental health issues may not be eligible. If you have questions about your eligibility or the study, it’s a good idea to speak with your healthcare provider.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male and female patients over the age of 18 years who have been diagnosed with a solid tumour and who are seen at the Barts Health NHS Trust for clinical management of their tumour.
- • 2. Male or female more than 18 years of age
- • 3. Able to participate in the study.
- • 4. Able to give informed consent.
- • 5. Patients enrolled into other clinical trials may be included into this study
- • Exclusion Criteria
- • 1. Any co-existing medical condition that in the Investigator's judgement will substantially increase the risk associated with the patient's participation in the study
- • 2. Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies
- • 3. Physical or mental health issues that preclude them from participation
About Queen Mary University Of London
Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials